hormone, was not associated with relapse. Patients who remained positive for antibodies after treatment tended to relapse within six months, but no relation with long term relapse was found. HLA-Cw7 but not HLA-DR3 was significantly associated with relapse. The presence of HLA-DR4 was significantly associated with remission and with absence ofantibodies to thyroid stimulating hormone receptor. HLA-DR4 may therefore protect against relapse of thyrotoxicosis by immunomodulation triggered by antithyroid drugs, which results in the synthesis of antibodies to the thyroid stimulating hormone receptor being inhibited. Introduction Graves' disease is characterised by hyperfunctioning of the thyroid, which is caused by antibodies to the thyroid stimulating hormone receptor.' 2 The natural course of the disease includes periods of spontaneous remission and recurrence.3 After treatment with thionamide drugs about 40-60% of patients relapse.3-5 The ability to predict recurrence is important as treatment by operation or with iodine-131 may be better for such patients. As relapse of hyperthyroidism is probably mediated immunologically'2 there may be immunological factors that are of prognostic value. Graves' disease is associated with the histocompatibility antigen HLA-DR3.26 Initially, the presence of HLA-DR3 and of antibody to the thyroid BRITISH MEDICAL JOURNAL VOLUME 296 7 MAY 1988 stimulating hormone receptor antibody at the end of treatment, alone and in combination, were reported to be predictors of short term relapse2 6-8; most workers, however, have been unable to relate long term outcome to the presence of We followed up 58 new patients with Graves' disease prospectively. The long term outcome after a 12 month course of antithyroid drugs was evaluated for a possible association with antibody to the thyroid stimulating hormone receptor and the full array of HLA-A, B, C, DR, and DQ antigens. Statistical analysis-The relation between relapse and the index of inhibition of thyroid stimulating hormone binding, HLA specificity, size of goitre, and eye signs was evaluated by x2 analysis (2 x 2 tables)'6 7; p values were not corrected for the number of antigens tested except where specified.
pneumonia, organism unspecified or Pneumocystis carinii pneumonia; most of the remainder were conditions known to be associated with but not specific to AIDS.
As the excess deaths were calculated only from the beginning of 1985, although some deaths due to AIDS are known to have occurred before then, the number underestimates the total deaths due to AIDS since the syndrome was first recognised in the United Kingdom. The 1984 baseline was adjusted to take account of the small increase in the population estimates of men in each succeeding year. Some of the excess deaths may not have been associated with HIV infection. If this were so the increase in deaths is difficult to explain, particularly as about 90% of them occurred in men who had never been married, and these men represent only 40% ofmen aged . The deficit of deaths due to causes other than those possibly related to HIV infection suggests that the selection was generally appropriate. The deficit of deaths among women aged Relapse of Graves' disease after treatment in 58 patients and its relation to presence or absence of HLA-DR4 and Cw7.
that the two patients positive for HLA-DR4 who relapsed were also positive for HLA-Cw7 whereas the nine others positive for HLA-DR4, who did not relapse, were negative for HLA-Cw7. The size of the goitre, which is an established risk factor for relapse, was found to be significantly greater in the patients who relapsed (2-35 (1 0) times normal size) than in those in remission (1-8 (0 6) times normal size) (p<001); eight of the 11 patients whose goitres were enlarged threefold relapsed within 48 months (p=024) (table I). The presence of eye signs could not be related to long term relapse (p=0 54), and the antithyroid drugs prescribed were not associated with relapse (data not shown).
Logistic regression analysis of data on HLA-Cw7 and DR4 specificities, threefold enlargement of the goitre, and the presence of antibody to the thyroid stimulating hormone receptor at the end of treatment showed that only HLA-Cw7 (estimated odds ratio 2-75, p=0003) and HLA-DR4 (estimated odds ratio 0-36, p=003) were significant and independent risk factors.
Discussion
Our 58 patients were representative of all patients with Graves' disease as the rate of recurrence of thyrotoxicosis within four years after treatment (55%) and the prevalence of eye signs (48%), HLA-B8 (36%) and HLA-DR3 (45%) antigens, autoimmune markers such as antibodies to the thyroid stimulating hormone receptor (57%), microsomal antibody (93%), and circulating immune complexes (72%) compared favourably with those reported previously.2469 319-22 The frequency of antibodies to the thyroid stimulating hormone receptor (57%) was lower than in our previous report (72%); we cannot explain this as the same assay was used in both studies.
Four of the five patients in our study who remained positive for antibody to thyroid stimulating hormone receptor during treatment relapsed. A similar association between antibodies during treatment and relapse has been reported in previous prospective studies.48202' As in other prospective studies,7-" however, we found that the presence of antibodies before treatment did not predict relapse; this conflicts with claims based on retrospective studies. 26 This difference in results may be due to an unwanted selection of patients but is not related to differences in duration of treatment or follow up.267 Enlargement of the goitre is a well known risk factor for relapse422 and often influences the management of patients with Graves' disease.22 The goitre was significantly larger in patients who relapsed than in those remaining in remission. Eye signs were not associated with relapse or presence of antibodies.
Our finding that HLA-DR3 did not predict relapse confirms the results of three other prospective studies.9-" The association of relapse with the presence of HLA-Cw7 and of remission with HLA-DR4 has not been reported previously; table III shows the combined influence of these phenotypes. In patients positive for HLA-Cw7 the absence or presence of DR4 did not seem to alter the increased risk of relapse; patients with an HLA-DR4 positive HLA-Cw7 negative phenotype seemed to be protected against relapse; and in those negative for both HLA-Cw7 and DR4 the numbers ofpatients who relapsed or were in remission were similar. The significance found for HLA-DR4 and Cw7, however, was lost when, as is customary in analysis in applied immunogenetics,'8 the p value was multiplied by the number of antigens tested. A relation between DR4 specificity and increased synthesis of microsomal antibody in postpartum thyroiditis has been described. 23 Previous reports showed that the prevalence of HLA-DR4 was not significantly decreased in patients with Graves' disease compared with the normal population. [24] [25] [26] No data are available on patients who relapsed; our results suggesting a relation between the presence of DR4 and remission and the presence of Cw7 and relapse therefore need to be confirmed. The presence of HLA-DR4 was also significantly associated with the absence of antibodies to the thyroid stimulating hormone receptor, whereas HLA-Cw7 specificity was not related to the presence or absence of antibodies or to other immunological variables. Notably, the four patients with antibodies to the receptor who relapsed were all negative for HLA-DR4 as expected but also for HLA-Cw7. The abnormal immune response in Graves' disease, which results in synthesis of autoantibodies against the thyroid stimulating hormone receptor, has been linked to the abnormal expression of HLA-DR and HLA-DQ on thyroid follicular cells27 and is associated with HLA-DR3. 6 The level of this antibody is known to decrease during antithyroid drug treatment.2 6-,, 25 21 Recently, numbers of activated T suppressor cells were shown to increase and numbers of activated T helper cells to decrease during drug treatment; this resulted in reduced synthesis of thyroid autoantibodies as indicated by lower serum titres.28 Our data suggest an association between the HLA-DR4 phenotype and both the absence of antibody to the thyroid stimulating hormone receptor and permanent remission after treatment. The HLA-DR4 phenotype may perhaps be associated with immunomodulation, which is probably enhanced by antithyroid drug treatment: in such people lymphocytes might have a decreased rate of synthesis of autoantibodies, which might eventually result in a higher chance of remission.
Our results support a recent hypothesis that some HLA antigens may promote the development of autoimmune disease whereas others may have a protective action.29
In conclusion, HLA-Cw7, antibodies to thyroid stimulating hormone receptor at the end of treatment, and a large goitre were found more commonly in patients who relapsed. The presence of HLA-DR4 as well as the absence of antibodies was associated with remission. HLA-DR4 may protect against relapse of thyrotoxicosis, possibly by immunomodulation resulting in inhibition of synthesis of pathogenic antibodies to the thyroid stimulating hormone receptor. as a group. Patients with myeloma or urinary tract tumours were not studied.
In many patients with malignancy the presence of proteinuria may be associated with a substantialiy reduced survival time.
Introduction Proteinuria, often heavy, is an infrequent but well recognised complication of many different malignancies.' 2 Histologically membranous nephropathy is most often present,34 but minimal change is typically found in patients with lymphomas.56 Tumour products were detected in glomeruli in a patient with colonic carcinoma,7 and tumour antigen was eluted from the kidneys of a patient with the nephrotic syndrome and malignant melanoma. 8 Renal tissue obtained at necropsy from patients who had reticuloendothelial tumours contained C3, immunoglobulins, and electron dense deposits in glomeruli,9 ' suggesting subclinical deposition of immune complexes. These observations were confirmed in patients who had died of gut tumours."
Low concentrations of proteinuria may be found in patients with advanced neoplastic disease'2 and extrarenal carcinomas.'3 The Framingham study showed that proteinuria was associated with increased mortality after controlling for cardiovascular risk factors.'4 The data are being examined to see whether proteinuria
